These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 8831919

  • 1. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
    Knipscheer HC, de Valois JC, van den Ende B, Wouter ten Cate J, Kastelein JJ.
    Atherosclerosis; 1996 Jul; 124 Suppl():S75-81. PubMed ID: 8831919
    [Abstract] [Full Text] [Related]

  • 2. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA, Fanghänel-Salmón G, Meza E, Montes J, Gulías-Herrero A, Sánchez L, Monterrubio-Flores EA, González-Valdez H, Gómez Pérez FJ.
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [Abstract] [Full Text] [Related]

  • 3. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
    Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H.
    Coron Artery Dis; 1996 Nov; 7(11):843-50. PubMed ID: 8993943
    [Abstract] [Full Text] [Related]

  • 4. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Mikhailidis DP, Jagroon IA.
    Metabolism; 2001 Nov; 50(11):1385-6. PubMed ID: 11715936
    [No Abstract] [Full Text] [Related]

  • 5. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M.
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
    Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG.
    Am J Cardiol; 1997 Sep 01; 80(5):608-13. PubMed ID: 9294990
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
    Turpin G, Bruckert E.
    Atherosclerosis; 1996 Jul 01; 124 Suppl():S83-7. PubMed ID: 8831920
    [Abstract] [Full Text] [Related]

  • 8. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
    de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C.
    Thromb Haemost; 1997 Jan 01; 77(1):75-9. PubMed ID: 9031453
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E, De Gennes JL, Malbecq W, Baigts F.
    Clin Cardiol; 1995 Nov 01; 18(11):621-9. PubMed ID: 8590530
    [Abstract] [Full Text] [Related]

  • 10. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
    Kockx M, de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C, Princen HM, Kooistra T.
    Thromb Haemost; 1997 Oct 01; 78(4):1167-72. PubMed ID: 9364979
    [Abstract] [Full Text] [Related]

  • 11. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
    Gajdos M, Mongiellová V, Huttová D, Cibulová L, Krivosíková Z, Spustová V, Dzúrik R.
    J Cardiovasc Pharmacol; 2001 Nov 01; 38(5):651-6. PubMed ID: 11602811
    [Abstract] [Full Text] [Related]

  • 12. Effect of ciprofibrate on C-reactive protein and fibrinogen levels.
    Rizos E, Kostoula A, Elisaf M, Mikhailidis DP.
    Angiology; 2002 Nov 01; 53(3):273-7. PubMed ID: 12025914
    [Abstract] [Full Text] [Related]

  • 13. Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
    Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Pehlivanidis AN, Kontopoulos AG.
    J Cardiovasc Risk; 2002 Feb 01; 9(1):33-9. PubMed ID: 11984215
    [Abstract] [Full Text] [Related]

  • 14. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
    Bruckert E, Dejager S, Chapman MJ.
    Atherosclerosis; 1993 Apr 01; 100(1):91-102. PubMed ID: 8318067
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.
    Wolf HR.
    Drugs Exp Clin Res; 1994 Apr 01; 20(3):109-13. PubMed ID: 7956717
    [Abstract] [Full Text] [Related]

  • 16. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN.
    Atherosclerosis; 1998 May 01; 138(1):217-25. PubMed ID: 9678787
    [Abstract] [Full Text] [Related]

  • 17. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
    Betteridge DJ, O'Bryan-Tear CG.
    Postgrad Med J; 1996 Dec 01; 72(854):739-43. PubMed ID: 9015467
    [Abstract] [Full Text] [Related]

  • 18. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
    Papadakis JA, Ganotakis ES, Jagroop IA, Winder AF, Mikhailidis DP.
    Int J Cardiol; 1999 Jun 01; 69(3):237-44. PubMed ID: 10402106
    [Abstract] [Full Text] [Related]

  • 19. Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
    Hernández-Mijares A, Lluch I, Vizcarra E, Martínez-Triguero ML, Ascaso JF, Carmena R.
    Nutr Metab Cardiovasc Dis; 2000 Feb 01; 10(1):1-6. PubMed ID: 10812581
    [Abstract] [Full Text] [Related]

  • 20. Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
    Hunninghake DB, Peters JR.
    Am J Med; 1987 Nov 27; 83(5B):44-9. PubMed ID: 3318453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.